Existing preclinical researches have clearly confirmed that paclitaxel combined IDO1 inhibitors would restore the proliferation ability and cytotoxic response of TILs and achieved synergistic antitumor effect in breast cancer and ovarian cancer (32, 41, 42). The gene discussed is IDO1; the disease is ovarian carcinoma.